Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.